logo
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients

FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients

CNN28-01-2025

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease, drugmaker Novo Nordisk said Tuesday.
A Phase 3 clinical trial found that injections of the semaglutide medication once weekly reduced the risk of kidney disease worsening by 24% in people who also had diabetes. It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.
Chronic kidney disease is a common complication for people living with type 2 diabetes. Diabetes is the leading cause of kidney failure, which is one of the leading causes of death in the US and worldwide; about a third of adults with diabetes also have chronic kidney disease, according to the US Centers for Disease Control and Prevention
The clinical trial tested the efficacy of Ozempic when added to the standard of care, not as a replacement for other treatments for disease management such as medicines to manage blood pressure, including ACE inhibitors and ARBs. About 3,500 adults across 28 countries were enrolled in the trial, which started in 2019 and followed participants for an average of about 3½ years.
The new indications, approved Tuesday by the FDA, make Ozempic the most broadly indicated drug in its class, with the largest set of specific medical conditions that it may be prescribed to treat.
Novo Nordisk is conducting a different study to understand how and why semgalutide seems to reduce the progression of kidney disease, said Stephen Gough, global chief medical officer and senior vice president at Novo Nordisk. But even though scientists don't fully understand the mechanisms behind them, the positive effects are strong: The clinical study was stopped early after reaching positive endpoints sooner than expected, and no new safety risks were identified in this trial, he said.
Get CNN Health's weekly newsletter
Sign up here to get The Results Are In with Dr. Sanjay Gupta every Friday from the CNN Health team. 'This really means something to the patients,' Gough told CNN. 'The impact on not just kidney disease but also cardiovascular disease and on all-cause death.'
Ozempic and other semaglutide injections such as Wegovy have been in short supply for years due to their rapid popularity. The FDA now lists Ozempic as 'available,' but there is still high demand.
'This is a medicine that's already available, both in diabetes clinics and now in renal clinics, so I would hope the uptake would start pretty quickly,' Gough said, adding that he hopes the confidence that comes with the data behind this approval will aid clinicians who are making daily decisions about how and when to use different treatments.
'It does help clinicians with their decision-making process, and it helps them focus those medicines to the patients who will benefit the most,' he said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Urgent dried fruit recall in 19 states over serious health risk
Urgent dried fruit recall in 19 states over serious health risk

Yahoo

time2 hours ago

  • Yahoo

Urgent dried fruit recall in 19 states over serious health risk

Dried fruit sold in multiple states has been recalled due to a serious health risk. Turkana Food Inc issued a recall on 352 cases of its Floria Dried Apricots, according to a press release shared by the U.S. Food and Drug Administration on Thursday. The product was recalled because it contains an undeclared allergen, sulfites, or 'chemicals used as preservatives' added to foods, beverages, and medications to prevent them from spoiling, according to the Cleveland Clinic. According to the FDA, the recall came after routine sampling, performed by the New York State Department of Agriculture, revealed that the product contained sulfites, which 'were not listed on the product labeling.' As Turkana Food Inc continues an 'investigation to correct the issue with the manufacturer,' production and distribution of the product by the FDA has been ceased. The recalled Floria Dried Apricots were sold at stores in 19 states: Alabama, California, Florida, Illinois, Indiana, Kentucky, Massachusetts, Maryland, Michigan, Missouri, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee, Texas, and Virginia. The product has the LOT number 440090478-15-333 on the bottom portion of the packaging. The UPC Label 2539560010 is marked by a sticker on the side of the packaging. The expiration date of November 2026 is also on the bottom of the packaging. Consumers who have the recalled product should not consume it. The FDA is also urging consumer to return the dried apricots to the place of purchase for a full refund. There have been no reported illnesses so far. Most often, people with asthma have allergies and sensitivities to sulfites. Earlier this week, P. East Trading Corp. also urgently recalled its Salted Smoked Split Herring because it may have been contaminated with Clostridium botulinum, a bacterium that can cause illness or death. Botulism is a rare but serious condition caused by a toxin that attacks the body's nerves. Symptoms include general weakness, dizziness, double-vision, trouble with speaking or swallowing, difficulty in breathing, abdominal distension, and constipation. Then, on Tuesday, 6,668 cases of Breyers Chocolate Truffle Ice Cream was also recalled following customer concerns that there was a mislabeling error. The recall came after it was found that the tubs actually contained Rocky Road ice cream. The Chocolate Truffle flavor has an allergen label that reads, 'may contain tree nuts,' while the Rocky Road flavor declares almonds as one of the ingredients. The last two years have also seen an alarming and unexplained rise in recalls. In 2024, approximately 300 food recalls were issued, with those recalls being linked to nearly 1,400 illnesses, a Public Interest Research Group report revealed. Out of the 1,400 illnesses, 487 people became sick enough to require hospitalization, and 19 people died. While those numbers are still low when weighed against the entire U.S. population, they are also double the number of hospitalizations and deaths from food-borne illnesses in 2023.

Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results
Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results

Yahoo

time2 hours ago

  • Yahoo

Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results

Insmed Incorporated (NASDAQ:INSM) is among the 10 Best Growth Stocks Under $100 to Buy Now. The shares of Insmed Incorporated (NASDAQ:INSM) have witnessed a surge of about 32% in the course of five days following the success of Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The results were evaluated about 24 hours after the administration of the drug, showcasing a consistent benefit throughout the 24-hour dosing period. Additionally, the company has revealed plans to initiate discussions with the U.S. Food and Drug Administration (FDA) to shape its Phase 3 trials roadmap. While this first Phase 3 trial will focus on pulmonary hypertension tied to interstitial lung disease by the year's end, the second trial is designed for PAH patients in the coming year. By 2032, the global market for pulmonary arterial hypertension is set to climb to $12.2 billion. A biopharmaceutical research team taking notes in front of a laboratory's microscope. The two anticipated phase 3 studies are enough to be excited about the company, yet there exists another breakthrough. Insmed Incorporated (NASDAQ:INSM) has finalized and submitted its New Drug Application (NDA) of brensocatib for treating patients with Non-cystic fibrosis bronchiectasis (NCFBE), with the date for review set for August 12, 2025. The company is indeed among the companies with high growth potential. Insmed Incorporated (NASDAQ:INSM) is a New Jersey-based biopharmaceutical company that develops and markets therapies to treat patients with serious and rare diseases. With a global presence, the company is committed to transforming the lives of many. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Check Your Freezer—Popular Ice Cream Recalled Due To Potentially Life-Threatening Allergen
Check Your Freezer—Popular Ice Cream Recalled Due To Potentially Life-Threatening Allergen

Yahoo

time2 hours ago

  • Yahoo

Check Your Freezer—Popular Ice Cream Recalled Due To Potentially Life-Threatening Allergen

Summer is just around the corner and ice cream is the quintessential warm weather treat. But if you have a carton or two chilling in your freezer, you might want to check the label. Breyers recently issued a recall on 6,668 cases of ice cream due to "undeclared allergens and mislabeled product." According to the FDA, the voluntary recall was initiated on June 2 because Breyers Rocky Road, which contains the almonds, was packaged incorrectly. The ice cream was packaged in Breyers Chocolate Truffle tubs with Rocky Road lids, which may be a concern for anyone who purchased the product and has a nut allergy. While almonds are a tree nut, the Chocolate Truffle tubs offer misleading ingredient information. The tubs say "may contain tree nuts" while the lids say "contain almonds." The FDA classified the recall as a Class II, which is defined as "a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." So how do you know if your ice cream is affected? Take a peek at the packaging of your Breyers ice cream tub. Affected products have the lot number: JUL1026GB3 and UPC code: 077567457288. In a statement to PEOPLE, Breyers says: "People with an almond allergy should not consume the product due to risk of serious or life-threatening allergic reaction. The safety and quality of our products is our top priority. For more information, consumers can visit or call 1-800-931-2826." You Might Also Like Insanely Easy Weeknight Dinners To Try This Week 29 Insanely Delicious Vodka Cocktails

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store